Member Info for marik

@victory12 a £7.50 per share by end of May would be nice. Any justification for the price?

I guess that's good news, am I right? ;-)

Is that positive? ;-)

Are we expecting an RNS next week around Monday?

"13th August 2003" your birthday ;-)

I presume ndn you've been reading it as Avacta doesn't want to combine the two technologies. Its the first paragraph on therapeutics page. Try and keep with the program.

"Avacta is developing novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and pre|CISIONTM tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current cancer immunotherapies as well as current high off-target toxicity experienced by most patients."

What does this say ndn?

"Its lead Affimer® programme is a PD-L1 antagonist which will form the basis of future bispecifics and TMAC drug conjugates. The lead pre|CISION™ programme is a tumour targeted form of Doxorubicin."

The aim is to get prescision and affimers linked that's what sets Avacta apart.

What you may not understand NDN is the aim of the study and the direction of what Alastair is trying to achieve. You've clearly no idea what TMAC signifies in the context of AVA6000 when you do, do get back.

Once the lft is commercialised, it will mark the first point at which affimers are verified. Many have simply estimated the value of LFT and not the enormous milestone in the use of affimers. In effect it opens multibillion dollar market which is valued well above covid-19 lft. The current mcap is likely to be dwarfed in due course. Alistair has reiterated this in every RNS by referring to the antibody market and as such has done a fantastic job.

From their website:

"Avacta expects to enter the clinic with its lead pre|CISION™ programme, a tumour activated form of doxorubicin, in early 2021."

That's in humans.

What worries me is the lack of knowledge on this board. If you don't know the basics you should be investing in something a little safer. Definitely not AIM.

It's been going on for years. When the bell rings 4.30, the derampers vanish. Then you are left with those who are genuinely concerned about their investments.

Surprise, surprise it happens every single time and it has happened here. Why is it that at 4.30 their concerns vanish along with them? They'll be back during the long weekend casting doubt for the coming week. As hard as it may feel, don't let them hijack a healthy debate on this board - whether positive or negative. I've learned over many years of investing to develop some tolerance this coming week. Avoid unneccessary arguments and don't respond to trolls or morons. Where possible validate claims with facts. Have genuinely researched views on the ready so that new and old investors can gain something beneficial and keep them visible.

Sng has an amazing drug on its way. It has the potential for a buy out. Anything positive in p3 and this will have offers on the table. The numbers are likely to be astounding. This takes time and effort to keep clean. Over ramping data at this point by RM could prove fatal for the long term prospects of a therapeutics company. Any potential buyer will want to see the numbers and avoid overhyped chaff. The presentation and results today was very positive for the long term. If your intention is day trading or shorting, then obviously you won't care about the long term prospects. However, once we approach eua or phase 3 results you'll be sitting on a lot of potential. I believe it will sail through.

GLA

I like the guy. He's young and has the guts to actually give a thought out opinion. He's not always right. But just for NDN17 I think I'll call him Messiah.

Myles "The Messiah" McNulty.

It's got something catchy about it.

I don't know man. Indian Gov have been hiding their numbers for months and pretending that there is nothing to see. They've banned all criticism on social media. I don't see them rushing to spend on drugs from abroad.

He must have had a reason to slate you. I'm sure he didn't out of the blue decide to have an issue with a random guy called ndn71. Is that his style?

Same happened last year, the price dropped to 32p, it was a great opportunity to buy heavy and then shot up. Seems like those complaining are wearing short term goggles.

Myles is not your Messiah, I get that, but for certain you've been more wrong than he has. Also he has some experience in the field which is more than I can say for you. Its evident from the childish mcnumpy comments, like your still at school. It doesn't come across well. That's why it's good for you to take a break once in a while and release the pressures of isolation from covid lockdown. One day you will look back and thank Avacta for it.

Super, if you feel that strongly i suggest you pack up and leave as well. The abc of investing is do your own research. If what you are saying is correct then they shouldn't have invested in the first place. I've been investing for over 2 decades, nothings changed apart from more idiots thinking they will get rich quick. Selling when they should be buying and vice versa. If you think that there are no shorters writing negative comments on here, then you are highly deluded yourself.

Ndn I think most of the comments are to you. Unfortunately, you have a very pessimistic view and you are coming across as a moaning Minnie. Maybe take a break for a short while.

It's very simple. There are those who are shorting trying to drive the price down. The presentation was standard for these p2 results, and Richard managed expectations well. No one was expecting miracles, but somehow the shorters are busy making out that these results were rubbish and that the ceo somehow messed things up.